Navigation Links
BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
Date:2/4/2010

inties.  Given these uncertainties, you should not place undue reliance on these forward-looking statements.  Some of the factors that could affect the forward-looking statements contained herein include: that to the extent peramivir is used as a treatment for H1N1 flu (or other strains of flu), there can be no assurance that it will prove effective; that HHS may further condition, reduce or eliminate future funding of the peramivir program; that ongoing peramivir clinical trials or our peramivir program in general may not be successful; that the pivotal trial with forodesine in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint; that development and commercialization of forodesine  in CTCL may not be successful; that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed; that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates; that our product candidates may not receive required regulatory clearances from the FDA; that ongoing and future pre-clinical and clinical development may not have positive results; that we or our licensees may not be able to continue future development of our current and future development programs; that our development programs may never result in future product, license or royalty payments being received by BioCryst; that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates; that our actual cash burn rate may not be consistent with our expectations; that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products a
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
2. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
3. BioCryst Announces Pricing of Public Offering of Common Stock
4. BioCryst to Present at Oppenheimer Healthcare Conference
5. Emergency Use Authorization Granted For BioCrysts Peramivir
6. BioCryst to Present at JMP Securities Healthcare Conference
7. BioCryst Clarifies Government Declaration Regarding Peramivir
8. BioCryst Provides Update Regarding Peramivir for Influenza
9. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
10. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
11. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... LONDON , September 4, 2015 ... & Vaccines  Allergic Rhinitis drugs ... revenues Where is the market for allergic ... this market? Visiongain ,s new report shows you ... opportunities and prospects. Our 326 page report ...
(Date:9/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gbd3bt/stability_testing ) ... of Pharmaceuticals (London, UK - December 2-3, 2015)" ... comprehensive two day seminar delegates will: - ... suitable for global arketing - Be able to ... and facilities - Know how to save resource ...
(Date:9/3/2015)... Report Details Ovarian Cancer ... Changes and Emerging Opportunities What,s the future for ... study forecasts those pharmaceutical revenues. There you find ... also explore trends, results, treatments, R&D, and opportunities, ... predictions to 2025 at overall world market, submarket, ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6
... Surgical Company (Nasdaq: STAA ) today announced that it will release ... Monday, November 2, 2009 after the market close. ... webcast on Tuesday, November 3, 2009 at 10:00 a.m. Eastern ... the Company,s third quarter results and current corporate developments. The timing ...
... SAN DIEGO, Oct. 27 Orexigen® Therapeutics, Inc. (Nasdaq: ... (ITT) analyses from the COR-I and COR-II Phase 3 trials ... stage Orexigen candidates for the treatment of obesity. These ... findings from a panel discussion on Saturday where the Company ...
Cached Medicine Technology:STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 3Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 4Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 5Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 6
(Date:9/4/2015)... ... September 04, 2015 , ... ... personal humidifying medical devices, announced its only mission and research focus: Water Life ... Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As a result ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... development of its first neighborhood created specifically for adults with intellectual, developmental and ... Phoenix Metro area and feature 30 cottage or “pocket” homes. In this community, ...
(Date:9/4/2015)... ... 04, 2015 , ... Steven Winter Associates, Inc., (SWA) is ... selected for the Residential Award of Merit by the Connecticut Green Building Council ... a highly competitive field of submissions, the net-zero energy residence will be honored ...
(Date:9/4/2015)... ... 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written ... the Pope’s upcoming trip to the United States. , Yisrayl lays out what he says ... Vatican and society is. Yisrayl also provides the meaning of his own name and describes ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... Vendormate nearly tripled its customer,base in 2008 and now ... the,U.S. in part because of economic uncertainty. Vendormate ... of supply chain,interruptions. , "With ... particular are anxious about their supply chain," said Andy,Monin, ...
... that the National Children,s Study will begin recruiting volunteers to take part ... affect children,s health. At a briefing, NIH officials announced that the first ... Carolina, and Queens, New York. , ... Washington, DC ...
... 13 Medarex, Inc. (Nasdaq: MEDX ... strong science-base and strategy for maximizing the value ... highlights of Medarex,s record of achievements in 2008, ... pipeline milestones in 2009, underscoring Medarex,s dedication to ...
... The Procter & Gamble Company (NYSE: PG ) ... the Common Stock and on the Series A and,Series B ... on,or after February 17, 2009 to shareholders of record at ... The company has been paying dividends without interruption ...
... Number One Cause of Death in Dogs Over 2MAF Canine Cancer Campaign ... owners and lovers in the United States view canine cancer as the ... One in four dogs die of cancer. Cancer is the ... Morris Animal Foundation (MAF) has posted on its ...
... DULUTH, Ga., Jan. 13 Metametrix Clinical Laboratory,( ... testing,services, announced the introduction of the new Fat-Soluble ... to measure a patient,s overall health,nutrient processing, and ... Fat-Soluble Vitamins Profile measures the following nutrients: , ...
Cached Medicine News:Health News:Economic Uncertainty Fuels Vendormate Growth in 2008 2Health News:National Children's Study Begins Recruiting Volunteers 2Health News:National Children's Study Begins Recruiting Volunteers 3Health News:National Children's Study Begins Recruiting Volunteers 4Health News:National Children's Study Begins Recruiting Volunteers 5Health News:Medarex Reviews Recent Highlights and Outlook for 2009 2Health News:Medarex Reviews Recent Highlights and Outlook for 2009 3Health News:Canine Cancer #1 Fear of Dog Lovers, Web Exclusive by Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners 2Health News:Canine Cancer #1 Fear of Dog Lovers, Web Exclusive by Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners 3Health News:Metametrix Introduces the New Fat-Soluble Vitamins Profile - A Snapshot of Overall Nutrition 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: